People: Aegerion Pharmaceuticals Inc (AEGR.O)
18 Jun 2013
Dr. Mark Sumeray, MD, MS, FRCS, has been appointed as Chief Medical Officer of Aegerion Pharmaceuticals, Inc., since August 2011. From November 2009 to July 2011, Dr. Sumeray served as Vice President, Cardiovascular/Metabolics U.S. Medical at Bristol-Myers Squibb, a pharmaceutical company. From December 2004 to November 2009, Dr. Sumeray held various positions at The Medicines Company, including Vice President and Business Unit Co-Leader, Vice President, Medical Business Development, and Vice President Clinical Development and Head of Medical Science. From September 2000 to October 2004, Dr. Sumeray served as worldwide Vice President of Clinical Development for the Ethicon Franchise of Johnson & Johnson. Dr. Sumeray received his B.Sc. degree in Physiology, his M.B.B.S. in medicine, and his M.D. in medicine, each from the University College London. Dr. Sumeray is a Fellow of the Royal College of Surgeons (FRCS) in the United Kingdom.
|Total Annual Compensation, USD||Long-Term Incentive Plans, USD||All Other, USD||Fiscal Year Total, USD|